sq-109 and Leishmaniasis--Cutaneous

Leishmania donovani is the causative agent of visceral leishmaniasis. Annually, 500 million new cases of infection are reported mainly in poor communities, decreasing the interest of the pharmaceutical industries. Therefore, the repositioning of new drugs is an ideal strategy to fight against these parasites. SQ109, a compound in phase IIb/III of clinical trials to treat resistant Mycobacterium tuberculosis, has a potent effect against Trypanosoma cruzi, responsible for Chagas' disease, and on Leishmania mexicana, the causative agent of cutaneous and muco-cutaneous leishmaniasis. In the latter, the toxic dose against intramacrophagic amastigotes is very low (IC

Topics: Adamantane; Animals; Cell Proliferation; Chagas Disease; Cytoplasm; Ethylenediamines; Humans; Leishmania donovani; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Membrane Potential, Mitochondrial; Mitochondria; Trypanosoma cruzi